Skip to Main Content

Paper Details

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS.
Neurology: Neuroimmunology and NeuroInflammation
32
2021
B cells, Blood Leukocytes, CD20, CD20+, CD4+, CD8+, CD8+ (, GM-CSF, Gd, IL-10, MS, Ocrelizumab, PPMS, Patients, T, T cells, T-cell compartment, TNF, blood immune cells, effector, memory, and regulatory cells, granulocyte-macrophage colony-stimulating factor, interferon-gamma, interleukin (IL)-6, monocyte, naive and memory B cells, ocrelizumab, patients, plasmablasts, primary progressive MS, sNfL, serum neurofilament light chain, tumor necrosis factor-alpha
Author NameAffiliation
Luis A García RodríguezRamon y Cajal University Hospital, Spain Neurologic Clinic and Policlinic (J.K., and Clinical Research, University Hospital Basel, University of Basel, La Princesa University Hospital, Madrid Multiple Sclerosis and Clinical Neuroimmunology Unit (J.M.-L., Virgen de la Arrixaca University Hospital, Vithas Nisa Sevilla Hospital Neurology Department (F.G.-G.), Valencia Clinic University Hospital Center of Neuroimmunology (A.S., Clinic of Barcelona Hospital, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), and Institut de Neurociencies, Universitat de Barcelona Neurology Department (Y.A.), Getafe University Hospital, Arnau de Vilanova Hospital, Lozano Blesa Clinic University Hospital, Alvaro Cunqueiro Hospital, Fuenlabrada University Hospital
  • 1 - 1

Datasets